|  |
| --- |
| **Regularly Scheduled Series**  **Hematology Oncology Grand Rounds**  **Department of Medicine/Section of Hematology/Oncology**  **University of Oklahoma Health Sciences Center**  **oulogo** |

**Course No. 22D12**

**Friday, April 22, 2022**

**8:00 – 9:15 a.m.**

**\* \* \* ZOOM PRESENTATION \* \* \***

Join Zoom Meeting

<https://zoom.us/j/95879607133?pwd=OElienJ6dFgxRFQrR042dldjVlM0QT09>

Meeting ID: 958 7960 7133

Passcode: 23414102

One tap mobile: 16027530140

**NOTE**: The meeting host will admit you to the meeting no earlier than 15 minutes before the scheduled start time. If you login early then please wait for the host to admit you.

Attending a Zoom meeting:

If you have not yet attended a Zoom meeting then please visit this site (below) for information you will need:

<https://support.zoom.us/hc/en-us/articles/201362193-Joining-a-Meeting>

Title:

**“The Conundrum of Thrombophilia Testing: How Much is Too Much and How Much is Too Little?”**

Presented by:



**Janna M. Journeycake, MD, MSCS**

Professor of Pediatrics  
Interim Section Chief of Pediatric Hematology/Oncology  
Director of Hematology,  
Jimmy Everest Section of Pediatric Hematology/Oncology  
University of Oklahoma Health Sciences Center

1. **Professional Practice Gap:** Thrombophilia testing is routinely performed on patients with thrombotic events and women with pregnancy loss, however we are uncertain that the results do or should cause providers to change acute management. There is also confusion about best timing for testing and what medications interfere with testing.
2. Many adults who are identified with a mild thrombophilia are placed on life-long anticoagulation. We do not clearly understand the risk of recurrent thrombotic events based on thrombophilia identified and what is the appropriate duration of therapy.
3. When adults are identified with a thrombophilia, it is often recommended that family members are tested, even very young children. This is a very debatable practice.

**Learning Objectives:** Upon completion of this session, participants will improve their competence and performance by being able to:

1. Recognize the pathophysiology of most of the inherited and acquired thrombophilias.
2. Discuss the appropriate testing to conduct and in which situations and comorbid conditions to perform testing.
3. Relate the importance of carefully recommending family testing for thrombophilias.

**Accreditation Statement:** The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Mitigation Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

**University Equal Opportunity / Non-Discrimination Statement:** The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides.

To file a grievance related to the non-discrimination policy, report sexual misconduct, and/or file a formal complaint of sexual misconduct, please utilize the reporting form at [link.ou.edu/reportingform](file:///\\dch-comd1\do\ocpd\22D%20RSS%20FY%202021-2022\22D%20To%20Do\link.ou.edu\reportingform).

Inquiries regarding non-discrimination policies may be directed to the Office(s) of Institutional Equity as may be applicable – Norman campus: (405) 325-3546/3549, Health Sciences Center: (405) 271-2110, or OU-Tulsa Title IX Office: (918) 660-3107. Additionally, individuals may visit [www.ou.edu/eoo](http://www.ou.edu/eoo).

**Accommodation Statement:**For accommodations on the basis of disability, call: 271-4022 ext. 48342.

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Policy on Planner and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

**Commercial and In-Kind Support:** This activity received no commercial or in-kind support.

**Acknowledgement of Commercial and In-Kind Support:** **Commercial support** is financial, or in-kind, contributions given by an ineligible company, which is used to pay all or part of the costs of a CME activity.  An ineligible company is any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity received no commercial or in-kind support.

**Disclosure & Mitigation Report**

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities.  We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity’s disclosure and mitigation information.

|  | | | **Nature of the Financial Relationship** | |
| --- | --- | --- | --- | --- |
| **Role** | **First Name** | **Last Name** | **Ineligible Company** | **Nature of the Financial Relationship** |
| Moderator/Planning Committee | Adam S. | Asch, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | |
| Planning Committee | Raid M. | Aljumaily, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | |
| Planning Committee | Rabia | Saleem, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | |
| Presenter | Janna | Journeycake, MD | Hema Biologics | Advisor |
| **Presenter:** The conflict was mitigated by Dr. Journeycake agreeing that the presentation will not include discussion of any products or services from any of the ineligible companies with which financial relationships exist and agreeing to refrain from making recommendations on topics in which the conflicts exists. This presentation will be evaluated by participants for fair balance. | | | | |
| Course Director | Mohamad O. | Khawandanah, MD | I have no financial relationships or affiliations with ineligible companies to disclose. | |
| Course Contact | Robin J. | Vinson | I have no financial relationships or affiliations with ineligible companies to disclose. | |

|  |
| --- |
| **Section of Hematology/Oncology**  **University of Oklahoma Health Sciences Center** |